| Company: | Retrophin, Inc. |
| Ticker Symbol: | RTRX |
| Class Period: | Mar-27-14 to Sep-30-14 |
| Date Filed: | Dec-1-14 |
| Lead Plaintiff Deadline: | Jan-30-15 |
| Court: | Southern District of California |
| Allegations: | |
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period stock grants to employees and that Retrophin' founder and Chief Executive Officer was trading Company stock in violation of the Company' Incentive Compensation Plan and other securities rules and that these trading irregularities included grants of shares in violation of the Company' Incentive Compensation Plan.
According to the complaint, following the Company' September 16, 2014 announcement that on September 15, 2014, it had reached an agreement with its Chief Financial Officer, Marc Panoff, pursuant to which Mr. Panoff' employment with the Company will terminate, effective as of February 28, 2015 and that on September 10, 2014, Jeffrey Paley, MD abruptly stepped down as a member of the Board of Directors and the Company' September 30, 2014 announcement its Board of Directors terminated its Chief Executive Officer, Martin Shkreli, effective immediately, the value of Retrophin shares declined significantly.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
